NCT04850378View on ClinicalTrials.gov

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Nephrotic SyndromeThromboembolic Disease
Interventions
DRUG

Dalteparin

Drug: Dalteparin 200 units/kg once a day for 4-7 days.

DRUG

Apixaban

Drug: Apixaban 5 mg twice a day for 4-7 days.

Trial Locations (1)

8200

Aarhus University Hospital, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT04850378 - Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome | Biotech Hunter | Biotech Hunter